Cresset, innovative provider of computational solutions and services for small molecule drug discovery and design, is pleased to announce the appointment of David Newble as Non-Executive Director.
Cresset expands its Board with the appointment of David Newble as Non-Executive Director
“I’m delighted to welcome David to the Cresset Board to advise and contribute to the continued growth of the company,” says Dr Robert Scoffin, CEO, Cresset. “David brings a wealth of experience in the life sciences, technology and services sectors, which will complement the existing skills and experiences around the Board table. We are looking forward to working with David as we continue to innovate and grow Cresset as a leading brand in life science research”.
“I am excited to be joining Cresset. The team have built a successful and highly innovative business and I am looking forward to working with them as they continue to grow and develop the business going forward.” says Dr David Newble, Non-Executive Director, Cresset.
Chemists in the world’s leading research organizations use Cresset software and discovery services to discover, design and optimize the best small molecules. Our patented software and expert scientists offer unrivalled insight into protein-ligand systems, enabling chemists to accelerate their research in industry sectors including: pharmaceuticals, agrochemicals, fine chemicals and flavors and fragrances. www.cresset-group.com
About David Newble
David Newble is Managing Director of SPT Labtech. He has a proven track record of growing life sciences companies, having previously headed up TAP Biosystems (now part of Sartorius Stedim Biotech).
Computational solutions for drug discovery